SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BIOMIRA RESEARCH (BIOM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote ()12/1/1999 12:53:00 AM
From: chirodoc  Read Replies (1) of 72
 
IMCL, BIOM, GZMO

thanks to IP

I think IMCL's C225 is a lot like Theratope in the sense that both vaccines have potential beyond the main researched cancer type. Theratope will have a larger market, however, by treating breast cancer as opposed to C225's application in head/neck. But both have the ability to expand from there, and should come out to be about the same in the end. IMCL also has that big anti-angiogensis project, but Biomira's BLP-25 is also big. C225 *might* get out there quicker though, I'd agree with that for sure.

GZMO, on the other hand, has the *best* corporate backing, being an off-shoot of GENZ. I've also heard great things about their science. But they are still early in development by comparison. Buy the pullbacks to 3 3/4 - 3 7/8 - this one always seems to come back to 4+.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News